Eli Lilly: new results for lebrikizumab
(CercleFinance.com) - New detailed results from Eli Lilly and Company's Phase 3 monotherapy studies in atopic dermatitis (AD) have shown that experimental lebrikizumab provided robust and lasting improvements in patients.
Lebrikizumab, a potent, high-affinity IL-13 inhibitor, showed similar results when given once every four weeks or once every two weeks.
Andrew Blauvelt, board-certified dermatologist, president of Oregon Medical Research Center said that " These data help deepen our understanding of the role lebrikizumab may play in treating atopic dermatitis and will assist practitioners to improve clinical outcomes for their patients with this chronic disease".
This has had no reaction however, with the share down almost 1% in early trading today.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Lebrikizumab, a potent, high-affinity IL-13 inhibitor, showed similar results when given once every four weeks or once every two weeks.
Andrew Blauvelt, board-certified dermatologist, president of Oregon Medical Research Center said that " These data help deepen our understanding of the role lebrikizumab may play in treating atopic dermatitis and will assist practitioners to improve clinical outcomes for their patients with this chronic disease".
This has had no reaction however, with the share down almost 1% in early trading today.
Copyright (c) 2022 CercleFinance.com. All rights reserved.